nivolumab,ipilimumab
bms
['nivo', 'ipi/', 'rcc,(-irccs),(-srcc),(-urcc)', 'novo ']
imdc analysis of 2l tx post-ipi/nivo (n=704) after d/c 1l ipi/nivo: 58% receive 2l tx imdc risk group, histology (ccrccvs non-cc), de-novo status, prior nx status, number and sites of metastases not predictive of receiving 2l therapy on mv analysis #asco23 
MD, MSc | @UofTUrology @SUO_YUO Fellow & @IHPMEUofT CEHCR PhD| Previously: @MCG_Urology and @AUB_Lebanon 🇱🇧